IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that MightySat™, a fingertip pulse oximeter designed for general wellness and health applications including sports, fitness, and relaxation management, is now available at Apple.com and select Apple retail stores in the US and Canada.
Masimo pulse oximeters, the leading brand in hospitals, provide accurate measurements when other pulse oximeters fail. By using a revolutionary invention called Signal Extraction Technology® (SET®), which allows oxygen saturation and pulse rate to be measured through challenging conditions including movement and low blood flow, the same high performance Masimo SET® technology used in hospitals is now available to Apple customers with MightySat.
The MightySat provides the following noninvasive measurements:
- Oxygen Saturation (SpO2)
- Pulse Rate (PR)
- Perfusion Index (PI)
In a study of 70 healthy volunteers during conditions of movement and low blood flow, Masimo SET® was the most accurate pulse oximeter when compared to 19 other hospital-grade pulse oximeters.1 SpO2 accuracy was defined as being within 7% of the reference value and pulse rate accuracy as being within 10%. Masimo SET® SpO2 was accurate 94% of the time while on average, the 19 other hospital-grade pulse oximeters were accurate only 60% of the time, with the least accurate only displaying accurate SpO2 27% of the time. Masimo SET® pulse rate was accurate 85% of the time while on average, the 19 other hospital-grade pulse oximeters were accurate only 27% of the time, with the least accurate only displaying accurate pulse rate 5% of the time.
Leading athletes and sports teams are increasingly using MightySat. “The reliable measurements of oxygen saturation and pulse rate from Masimo pulse oximeters were an important part of my training and recovery regimen to achieve peak athletic performance,” said Dotsie Bausch, 2012 Olympic medalist in cycling. “I trust MightySat to accurately track and trend my data on a daily basis and help me achieve optimal health, wellness, and fitness.”
MightySat users can display and track their data on a compatible iOS® device via the free Masimo Personal Health app available in the App Store. With user permission MightySat securely stores and trends measurements displayed in the Masimo Personal Health app in Apple’s Health app. With the most recent update, the Masimo Personal Health app also now features same-screen trending for all MightySat measurements.
@MasimoPersonalHealth | #MightySat
The MightySat fingertip pulse oximeter is intended for general wellness and health applications. For medical applications, Masimo offers the MightySat Rx, which is available to medical professionals.
- Barker S.J. Anesth Analg. 2002 Oct;95(4):967-72.
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo MightySat™. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our expectations regarding how retail customers will react to and benefit from the Masimo MightySat; risks related to our assumptions regarding the repeatability of study results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo MightySat, contribute to positive outcomes; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.